Experts worry insulin getting too expensive for many in U.S. and worldwide

Eric Palmer Healthcare professionals are concerned that hormone insulin meds, often the key diabetes treatment, are getting too costly for many patients, even in the U.S. In developing ...

It’s getting mighty crowded in biotech’s hippest neighborhood

Damian Garde Biotech's extended hot streak has put loads of money in the pockets of drugmakers, and nowhere is that clearer than in Cambridge, MA, where the boom has created demand ...

J&J getting ugly OTC episode behind it

Eric Palmer Sometime in the future, Johnson & Johnson expects it will not have to talk about the ugly fallout from its once-troubled Fort Washington, PA, OTC plant at every earnings ...

UPDATED: Reported Form 483 may explain Ranbaxy not getting Diovan to market

Eric Palmer Ranbaxy Laboratories had the 6-month exclusive right to produce a generic of Novartis' blockbuster hypertension fighter Diovan. But the patent loss came and went months ...

Avalere Study Shows Patients with Medicare Part D Have More Difficulty Getting Anticonvulsant Therapy

mia.burns Avalere Study Shows Patients with Medicare Part D Have More Difficulty Getting Anticonvulsant Therapy Than Those Commercially Insured Washington, D.C. – According to a ...

Are biotech IPOs already getting too hot to handle?

John Carroll Later this week a pair of biotechs–Cambridge, MA-based Epizyme and Israel's Kamada–are expected to join the lengthening list of drug developers going public ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS